HC Wainwright Reaffirms "Buy" Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 450.96% from the company's current price. HC Wainwright also issued estimates for Perspective Therapeutics' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.18) EPS.

Other analysts have also recently issued reports about the company. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, March 27th. Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Scotiabank began coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $14.44.

Perspective Therapeutics Stock Down 7.4 %

Perspective Therapeutics stock traded down $0.15 during trading hours on Monday, hitting $1.82. The company had a trading volume of 321,297 shares, compared to its average volume of 1,004,813. Perspective Therapeutics has a one year low of $1.80 and a one year high of $19.05. The firm has a 50-day moving average of $2.82 and a 200 day moving average of $6.04.

Insiders Place Their Bets

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 22,026 shares of the business's stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert F. Williamson III purchased 38,145 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was acquired at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the purchase, the director now owns 108,982 shares in the company, valued at approximately $233,221.48. The trade was a 53.85 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 115,696 shares of company stock worth $256,344 over the last ninety days. Corporate insiders own 3.52% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CATX. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $34,000. National Bank of Canada FI boosted its position in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth $51,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.